Grifols, S.A. (BME:GRF)

Market Cap	6.57B +18.1%
Revenue (ttm)	7.52B +7.3%
Net Income	372.72M +130.8%
EPS	0.55
Shares Out	680.51M
PE Ratio	19.73
Forward PE	12.18
Dividend	0.30 (2.78%)
Ex-Dividend Date	Aug 11, 2025

Volume	1,001,570
Average Volume	1,504,690
Open	10.77
Previous Close	10.79
Day's Range	10.75 - 11.00
52-Week Range	7.32 - 13.70
Beta	1.20
RSI	50.74
Earnings Date	Feb 25, 2026

About Grifols

Grifols, S.A. operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma, and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factor VIII/von Willebrand factor and factor IX, clotting factors for the treatment of hemophilia A an...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1909
• Employees: 23,800
• Stock Exchange: Madrid Stock Exchange
• Ticker Symbol: GRF

Financial Performance

In 2024, Grifols's revenue was 7.21 billion, an increase of 9.41% compared to the previous year's 6.59 billion. Earnings were 156.92 million, an increase of 270.81%.